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Treatment of gram - positive infections in critically
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Abstract
Gram-positive bacteria to include methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus
aureus (MSSA), and enterococci, to include vancomycin-resistant enterococci (VRE), display a remarkable array of resistance
and virulence factors, which have contributed to their prominent role in infections of the critically ill. Over the last three
decades infections with these pathogens has increased as has their overall resistance to available antimicrobial agents.
This has led to the development of a number of new antibiotics for the treatment of Gram-positive bacteria. At present, it
is important that clinicians recognize the changing resistance patterns and epidemiology of Gram-positive bacteria as
these factors may impact patient outcomes. The increasing range of these pathogens, such as the emergence of
community-associated MRSA clones, emphasizes that all specialties of physicians treating infections should have a good
understanding of the infections caused by Gram-positive bacteria in their area of practice. When initiating empiric
antibiotics, it is of vital importance that this therapy be timely and appropriate, as delays in treatment are associated
with adverse outcomes. Although vancomycin has traditionally been considered a first-line therapy for serious MRSA
infections, multiple concerns with this agent have opened the door for alternative agents demonstrating efficacy in
this role. Similarly, the expansion of VRE as a pathogen in the ICU setting has required the development of agents
targeting this important pathogen.
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Scope of the problem
Sepsis represents a major heath care problem with half of
the cases occurring in the critically ill and it is associated
with a high mortality (50% for septic shock) for intensive
care unit (ICU) patients [1,2]. The administration of early
appropriate antibiotics is recognized as one of the most
important interventions linked to improving patient out-
comes in sepsis [3-5]. The microbiology in the ICU has
changed in the last 2 to 3 decades so that Gram-positive
cocci (GPC) now represent one of the dominant species.
A recent survey showed that GPC cause the majority of
nosocomial infections with Staphylococcus aureus (16%,
with more than 50% being methicillin-resistant [MRSA])
and Enterococcus species (14%, with vancomycin-resistant
enterococci [VRE] accounting for approximately 3.5%
of all infections) predominating [6]. New resistance
patterns are also emerging to include vancomycin -
intermediate Staphylococcus aureus (VISA), increases
in the Staphylococcus aureus minimum inhibitory con-
centration (MIC) to vancomycin without breaching the
resistance threshold (i.e., MIC creep), vancomycin-resistant
Staphylococcus aureus (VRSA) due to acquisition of the
vanA gene, as well as daptomycin and linezolid resistance.
Given these newly described resistance patterns, testing for
susceptibility and adequate antibiotic dosing are of para-
mount importance for proper management of critically ill
infected patients.
For the purpose of this review we will focus on the con-
tribution of GPC to infections in critically ill patients em-
phasizing the agents available for their treatment. In the
ICU, respiratory tract infections especially pneumonia,
represent the most common infection and carry the high-
est mortality [2]. The microbiology of pneumonia varies
considerably based on the presence of risk factors for
antibiotic resistance. While most community-acquired
pneumonia (CAP) cases are caused by Streptococcus
pneumoniae, health care associated pneumonias (HCAPs),
particularly ventilator-associated pneumonia (VAP), are
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often caused by MRSA. Community-acquired MRSA
pneumonia can also occur and accounts for 3% of bac-
terial pneumonia cases [7], usually being associated
with younger patients, post-influenza, and necrotizing
pneumonia. The rates of penicillin and ceftriaxone re-
sistant strains of Streptococcus pneumoniae are rela-
tively low in adults [8]. However, macrolide resistance
can be seen in up to 30% of strains. Risk factors for re-
sistant pathogens appear to be identical for both CAP
and HCAP and include: prior hospitalization and anti-
biotics, immunosuppression, non-ambulatory status,
tube feeds and gastric acid suppressive agents [9].
With the advance of invasive devices (e.g. ventricular
assisted devices, intravenous catheters) has come a rise
in the incidence of bacteremia due to GPC. Along with
device removal and a meticulous search for metastatic
foci of infection (discitis, osteomyelitis, epidural abscess),
antibiotic treatment remains the cornerstone of therapy.
As will be discussed various choices are available for the
treatment of bacteremia due to GPC. When Staphylo-
coccus aureus is suspected, combination therapy with
an anti-staphylocccal penicillin (nafcillin, oxacillin) and
vancomycin should be considered until susceptibility
results are known [10]. Daptomycin has emerged as a
good alternative agent for Staphylococcus aureus bacteremia
and endocarditis [11]. It also offers the advantage of proven
efficacy in patients with MRSA bacteremia with vancomycin
MIC >1 mg/L and for infections attributed to heteroresis-
tant VISA, but not for VRSA [12,13]. Linezolid has also
been shown to have good activity as compared to vancom-
cyin in Staphylococcus aureus bacteremia [14].
Although less common than pneumonia and bacteremia,
complicated skin and soft tissue infections (SSTIs) can be
grave enough to warrant ICU care. Also, postsurgical site
infections can complicate ICU stays. The main pathogen
isolated in these infections is MRSA which makes empir-
ical coverage mandatory [15]. In recent years, most new
drugs targeting GPC (e.g. linezolid, ceftaroline, telavancin,
daptomcyin, tigecycline) have come to market by gaining
indication for treatment of SSTIs. Moreover, there are now
recognized subpopulations of patients with SSTIs who are
at increased risk of bacteremia necessitating more aggres-
sive and prolonged therapy [16,17].
Usually dominated by Gram - negative rods and anaer-
obes, health-care associated intra-abdominal infections
in debilitated patients often require empirical coverage
for enterococci including VRE. The true pathogenicity of
enterococci in these polymicrobial infections remains
unclear, but isolation of enterococci from peritoneal
fluid in severe infections was found to be an independ-
ent predictor of mortality [18]. So far, limited data are
available to formulate guideline recommendations for
the coverage of GPC except for VRE coverage in certain
high-risk patient populations (liver transplant recipients,
post-surgical complications in patients with prior antibi-
otics, patients undergoing hepatobilliary surgery, pa-
tients with known VRE colonization) [19].
Advances in the management of patients with neuro-
logic disorders and injuries have also resulted in increas-
ing occurrence of infections at these sites, particularly
with MRSA [20]. Although microbiology varies depend-
ing on type of intervention and antibiotic prophylaxis,
more than two thirds of the cases are due to Staphylo-
coccus species (approximately half of them Staphylococ-
cus aureus), with this percentage increasing over the last
two decades [21,22]. As with bacteremias and intravas-
cular infections, it is imperative to remove foreign de-
vices such as shunts and intraventricular catheters.
Treatment should include vancomycin and/or ceftriax-
one at doses that will insure adequate penetration into
the central nervous system (CNS). Linezolid has also
emerged as an alternative agent especially when van-
comcyin is not an option due to unachievable trough
levels or renal toxicity, due to excellent CNS penetra-
tion of linezolid even in the absence of inflamed men-
inges. Ceftaroline also appears to be an acceptable
agent for Streptococcus pneumoniae meningitis based
on animal data, but human studies are lacking. The
following section will focus on the available agents to
treat infections caused by GPC in critically ill patients.
Review
Linezolid
Linezolid is an oxazolidinone antibiotic that blocks as-
sembly of the initiation complex required for protein
synthesis providing broad activity against Gram-positive
bacteria with little to no Gram-negative activity [23].
Linezolid has high oral bioavailability (approximately
100%) with toxicity primarily being myelosuppression,
peripheral and optic neuropathy, lactic acidosis, and
serotonin syndrome [23]. Linezolid is indicated in the
US for vancomycin-resistant Enterococcus faecium (VRE)
infections, including bacteremia; nosocomial pneumonia
caused by Staphylococcus aureus (MSSA and MRSA), or
Streptococcus pneumoniae (including multi-drug resistant
strains [MDRSP]); complicated and uncomplicated SSTIs;
and CAP caused by Streptococcus pneumoniae (including
MDRSP) and MSSA.
The greatest utility of linezolid seems to be for the
treatment of Staphylococcus aureus infections, especially
nosocomial pneumonia [24-26]. This is especially true
for isolates with MICs > 1.0 mg/mL where linezolid ap-
pears to be a superior agent [26-28]. Linezolid is also in-
dicated for the treatment of necrotizing pneumonia
due to MSSA and MRSA strains secreting the Panton–
Valentine leukocidin (PVL) virulence factor given its
ability to block toxin production [29] and has been ex-
tensively studied for SSTIs, outperforming vancomycin
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in terms of clinical cures [30-35]. Linezolid has successfully
been used off label for the treatment of secondary MRSA
bacteremia [36,37], endocarditis [38,39], and central ner-
vous system infections [40-42]. The greater efficacy of li-
nezolid over vancomycin observed in some of the above
noted clinical studies may be due to the upward drifting
MICs of MSSA ansd MRSA to vancomycin as well as the
presence of heteroresistance to vancomycin, although not
all studies are consistent in demonstrating greater mortal-
ity with the presence of heteroresistance [43-50].
Like all other antibiotics, resistance to linezolid has
emerged and is a concern given the drug’s potent activity
for difficult to treat infections caused by GPC [51]. How-
ever, several new oxazolidinone antibiotics are in develop-
ment, including tedizolid in phase three clinical trials, that
offer advantages over linezolid to include coverage of
linezolid-resistant isolates and once daily dosing [52,53].
Daptomycin
Daptomycin is a bactericidal concentration-dependent lipo-
peptide that promotes the efflux of potassium out of bacte-
rial cells, leading to cell death. It is indicated for the
treatment of SSTIs (6 mg/kg) and Staphylococcus aureus
bloodstream infections (8 mg/kg) including right-sided
infective endocarditis, and it has been used off label for the
treatment of difficult central nervous system infections
caused by Gram-positive bacteria [52]. Daptomycin should
not be used for patients with pneumonia due to the inabil-
ity to establish non-inferiority to ceftriaxone in a clinical
trial, in large part due to the inhibition of daptomycin by
surfactant [54,55]. The main toxicities of daptomycin in-
clude eosinophilic pneumonia and skeletal muscle injury.
Guidelines from the Infectious Diseases Society of
America (IDSA) for the treatment of MRSA recom-
mend consideration of high-dose (10 mg/kg) dapto-
mycin in patients with persistent MRSA bacteremia
associated with vancomycin failure and possibly endo-
carditis [56]. These recommendations are grounded
on the concentration-dependent pharmacokinetic (PK)–
pharmacodynamic (PD) profile of daptomycin [57]. Sub-
optimal daptomycin area under the concentration-time
curve (AUC) values indexed to the minimum inhibitory
concentration (MIC), or AUC/MIC, have been linked to
clinical failure, whereas trough (Cmin) concentrations are
correlated with skeletal muscle toxicity [57,58]. Recently,
investigators observed high daptomycin clearance among
critically ill patients and significantly lower drug exposures
with the use of standard doses [59]. These investigators
suggest that daptomycin doses of 750 mg/day may be more
effective then the 6 to 8 mg/kg dosing, especially early on
when creatinine clearance and volume of distribution may
be augmented, especially in septic patients [59].
Several large multicenter observational case series have
documented the safety of high-dose daptomycin, to
include the treatment of VRE bacteremia which is also an
off label indication for its use [60-63]. Moreover, combin-
ation with a beta-lactam, trimethoprim/sulfamethoxazole,
rifampin or gentamicin have been recommended along
with higher dose daptomycin to avoid the emergence of
resistance when used as salvage therapy for vancomycin
treatment failures [52]. Clinicians should also be aware
that recurrent or breakthrough bacteremia following pro-
longed treatment of Staphylococcus aureus or enterococ-
cal infection, to include endocarditis, may signal the
emergence of daptomycin resistance, necessitating a
change in therapy [11,64].
Vancomycin
Vancomycin is a glycopeptides antibiotic with a number
of labeled indications for use in the US against GPC,
primarily MRSA, to include catheter-related infections,
Clostridium difficile-associated diarrhea (oral), compli-
cated infections in seriously ill patients, enterocolitis
due to Staphylococcus aureus (oral), Group B streptococcus
(neonatal prophylaxis), meningitis (with third-generation
cephalosporin for penicillin-resistant Streptococcus
pneumonia), pneumonia, prophylaxis against infective
endocarditis, and susceptible (MIC ≤1 mcg/mL) Gram-
positive infections. There are also many off-label indica-
tions where vancomycin is frequently used as first line
therapy to include bacteremia, central nervous system in-
fections due to MRSA (brain abscess, subdural empyema,
spinal epidural abscess), endocarditis (native valve or
prosthetic valve due to Enterococcus with vancomycin
MIC ≤4 mg/L, streptococci with penicillin MIC >0.5 mg/L
or patient intolerance to penicillin, or MRSA), endophthal-
mitis, SSTIs, prosthetic joint infections, and surgical
prophylaxis. The main toxicities of vancomycin for
concern in critically ill patients include hypersensitivity
reactions, renal toxicity and cytopenias.
The major current problem associated with increasing
vancomycin usage over the last several decades is the in-
creasing occurrence of treatment failures due to drug re-
sistance. Rising MICs to vancomycin appears to be the
main mechanism associated with these treatment fail-
ures [65]. Although uncommon, horizontal transfer of
the vanA operon from VRE has led to VRSA, while re-
peated exposure to vancomycin has allowed staphylo-
cocci to adapt under selective pressure leading to the
emergence of both VISA and heterogeneous-resistant
VISA (hVISA) [66,67]. Surveillance studies have reported
the prevalence of hVISA among clinical MRSA isolates
to be between zero and 74% [68-73]. The true preva-
lence of hVISA is difficult to determine since many insti-
tutions do not routinely screen for it and there are no
standardized methods for rapid detection of hVISA as
the ‘gold standard’ population analysis is labor intensive
to perform.
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Given the emerging resistance of GPC, especially MRSA,
to vancomycin, the IDSA has recommended that vanco-
mycin be administered according to body weight (15–
20 mg/kg/dose, actual body weight) every 8–12 hours, not
to exceed 2 g per dose, in patients with normal renal func-
tion (56). However, in seriously ill patients (eg, those with
sepsis, meningitis, pneumonia, or infective endocarditis)
with suspected MRSA infection, a loading dose of 25–
30 mg/kg (actual body weight) may be considered. Vanco-
mycin trough concentrations should be monitored in such
patients and maintained between 15–20 μg/mL. Unfortu-
nately, clinical studies do not support an association be-
tween greater vancomycin trough levels and improved
clinical outcomes supporting the use of alternative agents
when suspected or proven infection with high MIC
isolates is encountered [26,33,74,75]. Moreover, the
MIC test method has a significant impact on vanco-
mycin AUC/MIC estimation [76]. Clinicians should be
aware that the current target AUC/MIC of ≥400 for
vancomycin was derived using the reference broth
microdilution method and does not apply to the use of
other automated methods [76].
Ceftaroline
Ceftaroline is an anti-MRSA cephalosporin that was ap-
proved by the FDA in 2010 for the treatment of community-
acquired bacterial pneumonia (CABP) and acute bacterial
skin and soft structure infections (ABSSSI). Ceftaroline
works by binding to penicillin-binding proteins (PBPs) inhi-
biting their ability to function as transpeptidases in cell wall
synthesis. However, it is unique for its affinity for PBP2a and
PBP2x providing activity against MRSA and MDRSP includ-
ing ceftriaxone resistant strains [77]. The approved indica-
tions for ceftaroline include SSTIs and CAP at a dose of
600 mg every 12 hours. However, it is important to note that
the CAP trials only enrolled patients who were not critically
ill [77,78]. It is not clear whether the approved dose of cef-
taroline is adequate for critically ill patients with augmented
creatinine clearance and volumes of distribution. In critically
ill patients with normal or augmented renal function 600 mg
every 8 hours should be considered until more data become
available in this population.
Despite ceftaroline having activity against MRSA, little
data is available for its use in severe infections caused by
Gram-positive bacteria such as infective endocarditis or
osteomyelitis. However, a number of case series have re-
cently appeared suggesting that ceftaroline alone, or in
combination with another agent, can be used to treat
such infections attributed to MRSA or Enterococcus
faecalis [79-83]. Though limited clinical data support-
ing ceftaroline for hVISA, VISA or daptomycin non-
susceptible Staphylococcus aureus infections is currently
available, positive in vitro data exists to support such off
label use [84-86].
Tigecycline
Tigecycline is a glycylcycline, an analog of tetracyclines
with an extended spectrum of activity to include resist-
ant Gram-positive organisms such as MRSA, specific
resistant Gram-negative bacteria, to include the extended-
spectrum β-lactamase producing Enterobacteriaceae, and
as salvage therapy for susceptible strains of Acinetobacter
and other multi-drug resistant (MDR) pathogens. Tigecyc-
line is approved for use by the FDA and European
Medicines Agency (EMA) for adults with complicated
intra-abdominal infections (cIAIs) and SSTIs as well as
for CAP [87-89]. Tigecycline has also been used off
label for hospital-acquired pneumonia (HAP) and VAP,
diabetic foot infections, urinary tract infections (UTIs),
and refractory Clostridium difficile infection [90].
A major concern with the use of tigecycline in critic-
ally ill patients has to do with the current dosing which
is half of the originally planned dosing. This change was
made due to perceived unacceptable nausea and emesis
at the higher dose. Possibly as a result of this dosing
issue several meta-analyses have found the incidence of
death to be greater for tigecycline compared to the com-
parator antibiotics, this was most evident in the nosoco-
mial pneumonia studies [91-93]. However, this mortality
excess seems to be driven by infections with Gram-
negative bacteria, possible because standard tigecycline
doses provide serum concentrations that are below the
MICs of most Gram-negative pathogens. Moreover,
Ambrose et al. have proposed a tigecycline breakpoint
of 0.25 mg/L for Staphylococcus aureus and streptococci
classifying more isolates as resistant [94]. The use of
tigecycline in critically ill patients should be carefully
considered in light of the available clinical outcomes
data regarding its use.
Telavancin
Telavancin is a once-daily, intravenous, lipoglycopeptide
antibiotic approved in the USA for the treatment of
acute bacterial skin and skin structure infections due to
Gram-positive pathogens and has recently received ap-
proval for the treatment of HAP caused by these patho-
gens. Unlike other glycopeptides, telavancin maintains
its antimicrobial activity against pathogens with decreased
susceptibility to glycopeptides, including VISA and hVISA
strains, and exhibits more rapid concentration-dependent
bactericidal activity against susceptible organisms [95].
In two clinical trials of HAP due to Gram-positive
pathogens, particularly MRSA, treatment with telavan-
cin achieved higher cure rates in patients with mono-
microbial Staphylococcus aureus infection and cure rates
comparable to vancomycin in patients with MRSA in-
fection [96]. In patients with mixed Gram-positive/
Gram-negative infections, cure rates were higher in the
vancomycin group. Incidence and types of adverse events
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were comparable between the treatment groups. Mortality
rates for telavancin-treated versus vancomycin-treated pa-
tients were 21.5% versus 16.6% and 18.5% versus 20.6%
for the two trials. Increases in serum creatinine level were
more common in the telavancin group (16% vs 10%) [96].
Due to updated FDA guidance [97] for future anti-
biotic clinical trials of bacterial nosocomial pneumonia
that recommend using diagnostic criteria from the
American Thoracic Society/Infectious Diseases Society of
America (ATS/IDSA) guidelines [98], and using a primary
end point of 28-day all-cause mortality, a post-hoc reanaly-
sis of the two HAP studies was undertaken [99]. Clinical
cure rates at final follow-up were determined in the re-
fined all-treated (AT) and clinically-evaluable (CE) groups
(ATS/IDSA-AT and ATS/IDSA-CE, respectively) and the
exploratory end point of 28-day survival was evaluated in
the ATS/IDSA-AT group. Non-inferiority of telavancin
versus vancomycin was demonstrated, with similar cure
rates in the ATS/IDSA-AT (59% versus 59%, respectively)
and ATS/IDSA-CE groups (83% versus 80%, respectively).
Cure rates favored telavancin in ATS/IDSA-CE patients
where Staphylococcus aureus was the sole pathogen (86%
versus 75%). Overall, 28-day survival was similar in the
telavancin (76%) and vancomycin (77%) groups, but lower
in telavancin-treated patients with pre-existing moderate-
to-severe renal impairment (CLCR <50 ml/min). The FDA
approval indicates that telavancin should only be adminis-
tered to patients with moderate-to-severe renal impair-
ment if treatment benefit outweighs risk, or if no suitable
alternatives are available.
Conclusions
The rise in infections attributed to GPC in critically ill
patient mandates that clinicians treating these individ-
uals be familiar with the pathogen types, virulence fac-
tors, and susceptibilities of GPC in their local practice
areas. Moreover, the availability of MICs, especially for
vancomycin and daptomycin in MRSA, should help dir-
ect the use of these agents, as well as the new antimicro-
bials targeting GPC. This is especially important in
potentially life-threatening infections or infections asso-
ciated with foreign bodies. Moreover, there is a need for
the development of non-traditional agents such as vac-
cines and monoclonal antibodies directed against GPC
such as MRSA in order to help prevent these infections
and improve their outcomes [100].
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